首页> 美国卫生研究院文献>other >Sphingosine-1-Phosphate Receptor 5 Modulates Early-Stage Processes during Fibrogenesis in a Mouse Model of Systemic Sclerosis: A Pilot Study
【2h】

Sphingosine-1-Phosphate Receptor 5 Modulates Early-Stage Processes during Fibrogenesis in a Mouse Model of Systemic Sclerosis: A Pilot Study

机译:Sphingosine-1-磷酸受体5调节系统性硬化小鼠模型中纤维形成过程中的早期过程:一项先导研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Systemic sclerosis (SSc) is a rare multi-organ autoimmune disease characterized by progressive skin fibrosis. Inflammation, type 2 immunity, and fibrogenic processes are involved in disease development and may be affected by sphingolipids. However, details about early-stage pathophysiological mechanisms and implicated mediators remain elusive. The sphingolipid sphingosine-1-phosphate (S1P) is elevated in the sera of SSc patients, and its receptor S1P5 is expressed in skin tissue. Nevertheless, almost nothing is known about the dermatological contribution of S1P5 to inflammatory and pro-fibrotic processes leading to the pathological changes seen in SSc. In this study, we observed a novel effect of S1P5 on the inflammatory processes during low-dose bleomycin (BLM)-induced fibrogenesis in murine skin. By comparing 2-week-treated skin areas of wild-type (WT) and S1P5-deficient mice, we found that S1P5 is important for the transcriptional upregulation of the Th2 characteristic transcription factor GATA-3 under treatment-induced inflammatory conditions, while T-bet (Th1) and FoxP3 (Treg) mRNA expression was regulated independently of S1P5. Additionally, treatment caused a regulation of S1P receptor 1 and S1P receptor 3 mRNA as well as a regulation of long-chain ceramide profiles, which both differ significantly between the genotypes. Despite S1P5-dependent differences regarding inflammatory processes, similar macroscopic evidence of fibrosis was detected in the skin histology of WT and S1P5-deficient mice after 4 weeks of subcutaneous BLM treatment. However, at the earlier 2-week point in time, the mRNA data of pro-collagen type 1 and SMAD7 indicate a pro-fibrotic S1P5 contribution in the applied SSc mouse model. In conclusion, we propose that S1P5 plays a role as a novel modulator during the early phase of BLM-caused fibrogenesis in murine skin. An immediate relationship between dermal S1P5 expression and fibrotic processes leading to skin alterations, such as formative for SSc pathogenesis, is indicated but should be studied more profound in further investigations. Therefore, this study is an initial step in understanding the role of S1P5-mediated effects during early stages of fibrogenesis, which may encourage the ongoing search for new therapeutic options for SSc patients.
机译:系统性硬化症(SSc)是一种罕见的多器官自身免疫性疾病,其特征是进行性皮肤纤维化。炎症,2型免疫和纤维化过程与疾病发展有关,可能受到鞘脂的影响。但是,有关早期病理生理机制和牵连的介质的细节仍然难以捉摸。 SSc患者血清中的鞘脂鞘氨醇-1-磷酸(S1P)升高,并且其受体S1P5在皮肤组织中表达。尽管如此,关于S1P5对导致SSc发生病理变化的炎症和促纤维化过程的皮肤病学贡献几乎一无所知。在这项研究中,我们观察到S1P5对低剂量博来霉素(BLM)诱导的鼠皮肤纤维化过程中炎症过程的新作用。通过比较野生型(WT)和S1P5缺陷小鼠2周治疗的皮肤面积,我们发现S1P5对于在治疗诱导的炎症条件下Th2特征性转录因子GATA-3的转录上调很重要,而T -bet(Th1)和FoxP3(Treg)mRNA的表达不受S1P5的调节。另外,治疗引起对S1P受体1和S1P受体3mRNA的调节以及对长链神经酰胺谱的调节,这两者在基因型之间明显不同。尽管在炎症过程中S1P5依赖性存在差异,但在皮下BLM治疗4周后,WT和S1P5缺陷小鼠的皮肤组织学中发现了类似的纤维化宏观证据。但是,在更早的2周时间点,前胶原1型和SMAD7的mRNA数据表明在所应用的SSc小鼠模型中有促纤维化的S1P5贡献。总之,我们建议S1P5在小鼠皮肤BLM引起的纤维化的早期阶段起新型调节剂的作用。皮肤S1P5表达与导致皮肤改变的纤维化过程(例如SSc发病机制的形成)之间的直接关系已被指出,但应在更深入的研究中进行深入研究。因此,这项研究是了解S1P5介导的纤维化早期阶段的作用的第一步,这可能会鼓励为SSc患者寻找新的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号